Anti-influenza A virus characteristics of a fucoidan from sporophyll of Undaria pinnatifida in mice with normal and compromised immunity

Microbes and Infection

Volumn 15, Issue 4, 2013, Pages 302-309

  Hayashi, Kyoko ^a   Lee, Jung Bum ^a   Nakano, Takahisa ^b   Hayashi, Toshimitsu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b RIKEN VITAMIN CO LTD   (Japan)

Author keywords

Drug resistance; Immunocompromised animal; Influenza; Sulfated polysaccharide

Indexed keywords

FUCOIDIN; NEUTRALIZING ANTIBODY; OSELTAMIVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNITY; IMMUNOCOMPETENCE; INFLUENZA A; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNDARIA; UNDARIA PINNATIFIDA; VIRUS REPLICATION; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; DISEASE MODELS, ANIMAL; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; POLYSACCHARIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNDARIA; VIRUS REPLICATION;

ANIMALIA; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; PHAEOPHYCEAE; UNDARIA PINNATIFIDA;

EID: 84876096207     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.12.004     Document Type: Article

References (37)

1. Lui K.J., Kendal A.P. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health 1987, 77:712-716.
2. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Kraus S., Shortridge K.F., Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
3. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphil M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fetal respiratory illness. Science 1998, 279:393-396.
4. Yuen K.Y., Chan P.K., Peiris M., Tsang D.N., Que T.L., Shortridge K.F., Cheung P.T., To W.K., Ho E.T., Sung R., Cheng A.F. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351:467-471.
5. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., Gubareva L.V., Xu X., Bridges C.B., Uyeki T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360:2605-2615.
6. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., Straus S.E. Use of the oral NA inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999, 282:1240-1246.
7. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., Rode A., Kinnersley N., Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000, 355:1845-1850.
8. Hayden F.G., Osterhaus A.D., Treanor J.J., Fleming D.M., Aoki F.Y., Nicholson K.G., Bohnen A.M., Hirst H.M., Keene O., Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N. Engl. J. Med. 1997, 337:874-880.
9. Mist Study Group Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998, 352:1877-1881.
10. Monto A.S., Fleming D.M., Henry D., de Groot R., Makela M., Klein T., Eliott M., Keene O.N., Man C.Y. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. 1999, 180:254-261.
11. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
12. Arya V., Carter W., Robertson S. Role of clinical pharmacology to support the emergency use authorization (EUA) of an unapproved anti-influenza drug, peramivir. Clin. Pharmacol. Ther. 2010, 88:587-589.
13. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 264:759-765.
14. Gubareva L.V., Kaiser L., Metrosovich M.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 2001, 183:523-531.
15. Hayden F.G. Perspectives on antiviral use during pandemic influenza. Phil. Trans. Roy Soc. London 2001, 356:1877-1884.
16. Zambon M., Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antivir. Res. 2001, 49:147-156.
17. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St.George K., Epperson S., Brammer L., Klimov A.J., Bresee J.S., Fry A.M., Oseltamivir-Resistance Working Group Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
18. Ison M.G., Gubareva L.V., Atmar R.L., Treanor I., Hayden F.G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 2006, 193:760-764.
19. Ison M.G., Mishin V.P., Braciale T.J., Hayden F.G., Gubareva L.V. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 2006, 193:765-772.
20. Hosoya M., Balzarini J., Shigeta S., de Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother. 1991, 35:2515-2520.
21. Hosoya M., Shigeta S., Ishii T., Suzuki H., de Clercq E. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in vivo. J. Infect. Dis. 1993, 168:641-646.
22. Lee J.B., Hayashi K., Hashimoto M., Nakano T., Hayashi T. Novel antiviral fucoidan from sporophyll of Undaria pinnatifida (Mekabu). Chem. Pharm. Bull. 2004, 52:1091-1094.
23. Itoh H., Noda H., Amano H., Zuaug C., Mizuno T., Ito H. Antitumor activity and immunological properties of marine algal polysaccharides, especially fucoidan, prepared from Sargassum thunbergii of Phaeophyceae. Anticancer Res. 1993, 13:2045-2052.
24. Itoh H., Noda H., Amano H., Ito H. Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Anticancer Res. 1995, 15:1937-1948.
25. Hayashi T., Hayashi K., Kanekiyo K., Ohta K., Lee J.-B., Hashimoto M., Nakano T. Promising antiviral glyco-molecules from an edible alga. Combating the Threat of Pandemic Influenza: Drug Discovery Approaches 2007, 116-132. John Wiley & Sons, Inc., New York. P.F. Paul (Ed.).
26. Govorkova E.A., Fang H.B., Tan M., Webster R.G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob. Agents Chemother. 2004, 48:4855-4863.
27. Hayashi K., Nakano T., Hashimoto M., Kanekiyo K., Hayashi T. Defensive effects of a fucoidan from brown alga Undaria pinnatifida against herpes simplex virus infection. Int. Immunopharmacol. 2009, 8:109-116.
28. Ison M.G., Gnann J.W., Nagy-Agren S., Treannor J., Paya C., Steigbigel R., Elliott M., Weiss H.I., Hayden F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 2003, 8:183-190.
29. Leekha S., Zitterkopf N.L., Espy M.J., Smith T.F., Thompson R.L., Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect. Control Hosp. Epidemiol. 2007, 28:1071-1076.
30. McGeer A., Green K., Plevneshi A., Shigayeva A., Siddigi N., Raboud J., Low D.E., Toronto Invasive Bacterial Diseases Network Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 2007, 45:1568-1575.
31. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., Singh S., Kinnersley N., Ward P., Mills R.G. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2007, 283:1016-1024.
32. Clemons K.V., Gonzalez G.M., Singh G., Imai J., Espiritu M., Parmar R., Stevens D.A. Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob. Agents Chemother. 2006, 50:2650-2657.
33. Hofer M., Pospisil M., Vacek A., Hola J., Znojil V., Weiterova I., Streitiva D. Effects of adenosine A(3) receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice. J. Pharmacol. 2006, 538:163-167.
34. Escuret V., Frobert E., Bouscambert-Duchamp M., Sabatier M., Grog I., Valette M., Lina B., Morfin F., Ferraris O. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 2008, 41:25-28.
35. Yen H.L., Ilyushina N.A., Salomon R., Hoffmann E., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 2007, 81:12418-12426.
36. Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant variants. Antivir. Res. 2006, 70:121-131.
37. Ilyushina N.A., Hoffmann E., Solomon R., Webster R.G., Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 2007, 12:363-370.